LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 40

Search options

  1. Article: Overcoming mitochondrial dysfunction in neurodegenerative diseases.

    Pessoa, João / Duarte, Ana I

    Neural regeneration research

    2022  Volume 18, Issue 7, Page(s) 1486–1488

    Language English
    Publishing date 2022-12-26
    Publishing country India
    Document type Journal Article
    ZDB-ID 2388460-5
    ISSN 1876-7958 ; 1673-5374
    ISSN (online) 1876-7958
    ISSN 1673-5374
    DOI 10.4103/1673-5374.360279
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Type 2 Diabetes Induces a Pro-Oxidative Environment in Rat Epididymis by Disrupting SIRT1/PGC-1α/SIRT3 Pathway.

    Diniz, Antónia / Alves, Marco G / Candeias, Emanuel / Duarte, Ana I / Moreira, Paula I / Silva, Branca M / Oliveira, Pedro F / Rato, Luís

    International journal of molecular sciences

    2022  Volume 23, Issue 16

    Abstract: Diabetes mellitus type 2 (T2DM) has been associated with alterations in the male reproductive tract, especially in the epididymis. Although it is known that T2DM alters epididymal physiology, disturbing mitochondrial function and favoring oxidative ... ...

    Abstract Diabetes mellitus type 2 (T2DM) has been associated with alterations in the male reproductive tract, especially in the epididymis. Although it is known that T2DM alters epididymal physiology, disturbing mitochondrial function and favoring oxidative stress, the mechanisms remain unknown. Sirtuin 1 (SIRT1), peroxisome proliferators-activated receptor γ coactivator 1α (PGC-1α), and sirtuin 3 (SIRT3) are key regulators of mitochondrial function and inducers of antioxidant defenses. In this study, we hypothesized that the epididymal SIRT1/PGC-1α/SIRT3 axis mediates T2DM-induced epididymis dysfunction by controlling the oxidative profile. Using 7 Goto-Kakizaki (GK) rats (a non-obese model that spontaneously develops T2DM early in life), and 7 age-matched Wistar control rats, we evaluated the protein levels of SIRT1, PGC-1α, and SIRT3, as well as the expression of mitochondrial respiratory complexes. The activities of epididymal glutathione peroxidase (GPx), glutathione reductase (GR), superoxide dismutase (SOD), and catalase (CAT) were determined, as well as the epididymal antioxidant capacity. We also evaluated protein nitration, carbonylation, and lipid peroxidation in the epididymis. The T2DM rats presented with hyperglycemia and glucose intolerance. Epididymal levels of SIRT1, PGC-1α, and SIRT3 were decreased, as well as the expression of the mitochondrial complexes II, III, and V, in the T2DM rats. We found a significant decrease in the activities of SOD, CAT, and GPx, consistent with the lower antioxidant capacity and higher protein nitration and lipid peroxidation detected in the epididymis of the T2DM rats. In sum, T2DM disrupted the epididymal SIRT1/PGC-1α/SIRT3 pathway, which is associated with a compromised mitochondrial function. This resulted in a decline of the antioxidant defenses and an increased oxidative damage in that tissue, which may be responsible for the impaired male reproductive function observed in diabetic men.
    MeSH term(s) Animals ; Antioxidants/metabolism ; Diabetes Mellitus, Type 2/metabolism ; Epididymis/metabolism ; Humans ; Male ; Oxidative Stress/physiology ; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha/metabolism ; Rats ; Rats, Wistar ; Sirtuin 1/metabolism ; Sirtuin 3/metabolism ; Superoxide Dismutase/metabolism
    Chemical Substances Antioxidants ; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha ; Superoxide Dismutase (EC 1.15.1.1) ; SIRT1 protein, human (EC 3.5.1.-) ; SIRT3 protein, human (EC 3.5.1.-) ; Sirt1 protein, rat (EC 3.5.1.-) ; Sirtuin 1 (EC 3.5.1.-) ; Sirtuin 3 (EC 3.5.1.-)
    Language English
    Publishing date 2022-08-10
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms23168912
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Clinical experience of a cardio-oncology consultation at a tertiary university hospital in Portugal: An observational study.

    Fiuza, Manuela / Magalhães, Andreia / Nobre Menezes, Miguel / Costa, Paula / Abreu Ribeiro, Leonor / Abreu, Catarina / Brás, Raquel / Vieira, Joana / Duarte, Ana I / Morais, Pedro / Silva, Beatriz / Costa, Luís / Pinto, Fausto J

    Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology

    2022  

    Abstract: Introduction: Heart disease and cancer are the two leading causes of morbidity and mortality worldwide. Advances in cancer screening and management have led to longer survival and better quality of life. Despite this progress, many cancer patients ... ...

    Abstract Introduction: Heart disease and cancer are the two leading causes of morbidity and mortality worldwide. Advances in cancer screening and management have led to longer survival and better quality of life. Despite this progress, many cancer patients experience cardiovascular complications during and after cancer treatment. This study describes the experience of a cardio-oncology program at tertiary academic hospital.
    Methods: In this retrospective observational study, cancer patients referred to the CHULN cardio-oncology consultation (COC) between January 2016 and December of 2019 were included. Data collected included: patient demographics, cancer type, reason for referral, cardiovascular risk factors, cardiac and oncologic treatments and clinical outcomes.
    Results: A total of 520 patients (mean age: 65 ± 14 years; 65% women) were referred to the COC. The main reasons for referral were suspected heart failure (26%), pre-high risk chemotherapy assessment (20%) and decreased LVEF (15%). Pre-existing cardiovascular risk factors were common (79%) and 309 (59%) were taking cardiac medications. The most common type of malignancy was breast cancer (216, 41%) followed by gastrointestinal (139, 27%). More than half received anthracycline-based regimens (303, 58%). Most patients (401; 77%) successfully completed cancer therapy. At the time of last data collection, the majority of patients were alive (430, 83%). Cardiac-related mortality was observed in 16%.
    Conclusions: The close collaboration between cardiology and oncology teams and timely cardiac monitoring was the key to the majority of patients to completing their prescribed cancer therapy.
    Language Portuguese
    Publishing date 2022-09-21
    Publishing country Portugal
    Document type Journal Article
    ZDB-ID 632718-7
    ISSN 2174-2030 ; 0870-2551 ; 0304-4750
    ISSN (online) 2174-2030
    ISSN 0870-2551 ; 0304-4750
    DOI 10.1016/j.repc.2021.07.014
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Dual Therapy with Liraglutide and Ghrelin Promotes Brain and Peripheral Energy Metabolism in the R6/2 Mouse Model of Huntington's Disease.

    Duarte, Ana I / Sjögren, Marie / Santos, Maria S / Oliveira, Catarina R / Moreira, Paula I / Björkqvist, Maria

    Scientific reports

    2018  Volume 8, Issue 1, Page(s) 8961

    Abstract: Neuronal loss alongside altered energy metabolism, are key features of Huntington's disease (HD) pathology. The orexigenic gut-peptide hormone ghrelin is known to stimulate appetite and affect whole body energy metabolism. Liraglutide is an efficient ... ...

    Abstract Neuronal loss alongside altered energy metabolism, are key features of Huntington's disease (HD) pathology. The orexigenic gut-peptide hormone ghrelin is known to stimulate appetite and affect whole body energy metabolism. Liraglutide is an efficient anti-type 2 diabetes incretin drug, with neuroprotective effects alongside anorectic properties. Combining liraglutide with the orexigenic peptide ghrelin may potentially promote brain/cognitive function in HD. The R6/2 mouse model of HD exhibits progressive central pathology, weight loss, deranged glucose metabolism, skeletal muscle atrophy and altered body composition. In this study, we targeted energy metabolism in R6/2 mice using a co-administration of liraglutide and ghrelin. We investigated their effect on brain cortical hormone-mediated intracellular signalling pathways, metabolic and apoptotic markers, and the impact on motor function in HD. We here demonstrate that liraglutide, alone or together with ghrelin (subcutaneous daily injections of 150 µg/kg (ghrelin) and 0.2 mg/kg (liraglutide), for 2 weeks), normalized glucose homeostatic features in the R6/2 mouse, without substantially affecting body weight or body composition. Liraglutide alone decreased brain cortical active GLP-1 and IGF-1 levels in R6/2 mice, alongside higher ADP levels. Liraglutide plus ghrelin decreased brain insulin, lactate, AMP and cholesterol levels in R6/2 mice. Taken together, our findings encourage further studies targeting energy metabolism in HD.
    MeSH term(s) Animals ; Brain/metabolism ; Brain/pathology ; Disease Models, Animal ; Drug Therapy, Combination ; Energy Metabolism/drug effects ; Ghrelin/pharmacology ; Humans ; Huntington Disease/drug therapy ; Huntington Disease/genetics ; Huntington Disease/metabolism ; Huntington Disease/pathology ; Liraglutide/pharmacology ; Male ; Mice ; Mice, Transgenic
    Chemical Substances Ghrelin ; Liraglutide (839I73S42A)
    Language English
    Publishing date 2018-06-12
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2615211-3
    ISSN 2045-2322 ; 2045-2322
    ISSN (online) 2045-2322
    ISSN 2045-2322
    DOI 10.1038/s41598-018-27121-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: The interplay between redox signalling and proteostasis in neurodegeneration: In vivo effects of a mitochondria-targeted antioxidant in Huntington's disease mice.

    Pinho, Brígida R / Duarte, Ana I / Canas, Paula M / Moreira, Paula I / Murphy, Michael P / Oliveira, Jorge M A

    Free radical biology & medicine

    2019  Volume 146, Page(s) 372–382

    Abstract: Abnormal protein homeostasis (proteostasis), dysfunctional mitochondria, and aberrant redox signalling are often associated in neurodegenerative disorders, such as Huntington's (HD), Alzheimer's and Parkinson's diseases. It remains incompletely ... ...

    Abstract Abnormal protein homeostasis (proteostasis), dysfunctional mitochondria, and aberrant redox signalling are often associated in neurodegenerative disorders, such as Huntington's (HD), Alzheimer's and Parkinson's diseases. It remains incompletely understood, however, how changes in redox signalling affect proteostasis mechanisms, including protein degradation pathways and unfolded protein responses (UPR). Here we address this open question by investigating the interplay between redox signalling and proteostasis in a mouse model of HD, and by examining the in vivo effects of the mitochondria-targeted antioxidant MitoQ. We performed behavioural tests in wild-type and R6/2 HD mice, examined markers of oxidative stress, UPR activation, and the status of key protein degradation pathways in brain and peripheral tissues. We show that R6/2 mice present widespread markers of oxidative stress, with tissue-specific changes in proteostasis that were more pronounced in the brain and muscle than in the liver. R6/2 mice presented increased levels of cytosolic and mitochondrial chaperones, particularly in muscle, indicating UPR activation. Treatment with MitoQ significantly ameliorated fine motor control of R6/2 mice, and reduced markers of oxidative damage in muscle. Additionally, MitoQ attenuated overactive autophagy induction in the R6/2 muscle, which has been associated with muscle wasting. Treatment with MitoQ did not alter autophagy markers in the brain, in agreement with its low brain bioavailability, which limits the risk of impairing neuronal protein clearance mechanisms. This study supports the hypotheses that abnormal redox signalling in muscle contributes to altered proteostasis and motor impairment in HD, and that redox interventions can improve muscle performance, highlighting the importance of peripheral therapeutics in HD.
    MeSH term(s) Animals ; Antioxidants/metabolism ; Antioxidants/pharmacology ; Disease Models, Animal ; Huntington Disease/drug therapy ; Huntington Disease/genetics ; Huntington Disease/metabolism ; Mice ; Mice, Transgenic ; Mitochondria/metabolism ; Oxidation-Reduction ; Proteostasis
    Chemical Substances Antioxidants
    Language English
    Publishing date 2019-11-18
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 807032-5
    ISSN 1873-4596 ; 0891-5849
    ISSN (online) 1873-4596
    ISSN 0891-5849
    DOI 10.1016/j.freeradbiomed.2019.11.021
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Ghrelin rescues skeletal muscle catabolic profile in the R6/2 mouse model of Huntington's disease.

    Sjögren, Marie / Duarte, Ana I / McCourt, Andrew C / Shcherbina, Liliya / Wierup, Nils / Björkqvist, Maria

    Scientific reports

    2017  Volume 7, Issue 1, Page(s) 13896

    Abstract: Accumulating evidence suggests altered energy metabolism as a key feature in Huntington's disease (HD) pathology. Hyper-catabolism, including weight loss and muscle atrophy, is seen in HD patients and HD mouse models. Metabolic hormones are key players, ... ...

    Abstract Accumulating evidence suggests altered energy metabolism as a key feature in Huntington's disease (HD) pathology. Hyper-catabolism, including weight loss and muscle atrophy, is seen in HD patients and HD mouse models. Metabolic hormones are key players, not only in energy metabolism, but also in neurodegenerative processes. Ghrelin, a gut peptide-hormone, plays an important role in regulating energy metabolism, stimulating appetite, and affects brain function and increases neuronal survival. The R6/2 mouse model of HD has previously been shown to exhibit progressive weight loss, dysregulated glucose metabolism, skeletal muscle atrophy and altered body composition. In this study, we targeted energy metabolism in R6/2 mice using ghrelin administration, with the primary aim to delay weight loss and reduce muscle atrophy. We also evaluated glucose metabolism and behaviour. We here demonstrate that ghrelin administration (subcutaneous 150 μg/kg daily injections) for 4 weeks, reversed the catabolic gene expression profile (increased expression of Caspase 8, Traf-5 and Creb1) seen in R6/2 mouse skeletal muscle. Skeletal muscle morphology was also improved with ghrelin, and importantly, ghrelin administration normalized behavioural deficits in R6/2 mice. Taken together, our findings encourage further studies targeting metabolism in HD.
    MeSH term(s) Adipose Tissue, White/drug effects ; Adipose Tissue, White/metabolism ; Animals ; Biomarkers/blood ; Disease Models, Animal ; Fatty Acids/metabolism ; Ghrelin/pharmacology ; Ghrelin/therapeutic use ; Glucose/metabolism ; Homeostasis/drug effects ; Humans ; Huntington Disease/blood ; Huntington Disease/complications ; Huntington Disease/drug therapy ; Huntington Disease/metabolism ; Liver/drug effects ; Liver/metabolism ; Male ; Mice ; Muscle, Skeletal/drug effects ; Muscle, Skeletal/metabolism ; Muscle, Skeletal/pathology ; Muscular Atrophy/complications ; Muscular Atrophy/drug therapy ; Nesting Behavior/drug effects ; Rats
    Chemical Substances Biomarkers ; Fatty Acids ; Ghrelin ; Glucose (IY9XDZ35W2)
    Language English
    Publishing date 2017-10-24
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2615211-3
    ISSN 2045-2322 ; 2045-2322
    ISSN (online) 2045-2322
    ISSN 2045-2322
    DOI 10.1038/s41598-017-13713-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Insulin in central nervous system: more than just a peripheral hormone.

    Duarte, Ana I / Moreira, Paula I / Oliveira, Catarina R

    Journal of aging research

    2012  Volume 2012, Page(s) 384017

    Abstract: Insulin signaling in central nervous system (CNS) has emerged as a novel field of research since decreased brain insulin levels and/or signaling were associated to impaired learning, memory, and age-related neurodegenerative diseases. Thus, besides its ... ...

    Abstract Insulin signaling in central nervous system (CNS) has emerged as a novel field of research since decreased brain insulin levels and/or signaling were associated to impaired learning, memory, and age-related neurodegenerative diseases. Thus, besides its well-known role in longevity, insulin may constitute a promising therapy against diabetes- and age-related neurodegenerative disorders. More interestingly, insulin has been also faced as the potential missing link between diabetes and aging in CNS, with Alzheimer's disease (AD) considered as the "brain-type diabetes." In fact, brain insulin has been shown to regulate both peripheral and central glucose metabolism, neurotransmission, learning, and memory and to be neuroprotective. And a future challenge will be to unravel the complex interactions between aging and diabetes, which, we believe, will allow the development of efficient preventive and therapeutic strategies to overcome age-related diseases and to prolong human "healthy" longevity. Herewith, we aim to integrate the metabolic, neuromodulatory, and neuroprotective roles of insulin in two age-related pathologies: diabetes and AD, both in terms of intracellular signaling and potential therapeutic approach.
    Language English
    Publishing date 2012-02-21
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2573906-2
    ISSN 2090-2212 ; 2090-2212
    ISSN (online) 2090-2212
    ISSN 2090-2212
    DOI 10.1155/2012/384017
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Liraglutide Protects Against Brain Amyloid-β

    Duarte, Ana I / Candeias, Emanuel / Alves, Inês N / Mena, Débora / Silva, Daniela F / Machado, Nuno J / Campos, Elisa J / Santos, Maria S / Oliveira, Catarina R / Moreira, Paula I

    International journal of molecular sciences

    2020  Volume 21, Issue 5

    Abstract: Alzheimer's disease (AD) is the most common form of dementia worldwide, being characterized by the deposition of senile plaques, neurofibrillary tangles (enriched in the amyloid beta (Aβ) peptide and hyperphosphorylated tau (p-tau), respectively) and ... ...

    Abstract Alzheimer's disease (AD) is the most common form of dementia worldwide, being characterized by the deposition of senile plaques, neurofibrillary tangles (enriched in the amyloid beta (Aβ) peptide and hyperphosphorylated tau (p-tau), respectively) and memory loss. Aging, type 2 diabetes (T2D) and female sex (especially after menopause) are risk factors for AD, but their crosslinking mechanisms remain unclear. Most clinical trials targeting AD neuropathology failed and it remains incurable. However, evidence suggests that effective anti-T2D drugs, such as the GLP-1 mimetic and neuroprotector liraglutide, can be also efficient against AD. Thus, we aimed to study the benefits of a peripheral liraglutide treatment in AD female mice. We used blood and brain cortical lysates from 10-month-old 3xTg-AD female mice, treated for 28 days with liraglutide (0.2 mg/kg, once/day) to evaluate parameters affected in AD (e.g., Aβ and p-tau, motor and cognitive function, glucose metabolism, inflammation and oxidative/nitrosative stress). Despite the limited signs of cognitive changes in mature female mice, liraglutide only reduced their cortical Aβ
    MeSH term(s) Alzheimer Disease/metabolism ; Amyloid beta-Peptides/metabolism ; Animals ; Behavior, Animal ; Brain/metabolism ; Cyclic AMP-Dependent Protein Kinases/metabolism ; Diabetes Mellitus, Type 2/metabolism ; Estradiol/metabolism ; Female ; Glucagon-Like Peptide 1/metabolism ; Glycolysis ; Hypoglycemic Agents/pharmacology ; Inflammation/metabolism ; Liraglutide/pharmacology ; Maze Learning ; Memory Disorders ; Mice ; Neurofibrillary Tangles/metabolism ; Nitrosative Stress ; Oxidative Stress ; Peptide Fragments/metabolism ; Phenotype ; Plaque, Amyloid/metabolism
    Chemical Substances Amyloid beta-Peptides ; Hypoglycemic Agents ; Peptide Fragments ; amyloid beta-protein (1-42) ; Estradiol (4TI98Z838E) ; Liraglutide (839I73S42A) ; Glucagon-Like Peptide 1 (89750-14-1) ; Cyclic AMP-Dependent Protein Kinases (EC 2.7.11.11)
    Language English
    Publishing date 2020-03-04
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms21051746
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Dipeptidyl peptidase-4 inhibitors and sulfonylureas prevent the progressive impairment of the nigrostriatal dopaminergic system induced by diabetes during aging.

    Lietzau, Grazyna / Magni, Giulia / Kehr, Jan / Yoshitake, Takashi / Candeias, Emanuel / Duarte, Ana I / Pettersson, Hans / Skogsberg, Josefin / Abbracchio, Maria P / Klein, Thomas / Nyström, Thomas / Ceruti, Stefania / Darsalia, Vladimer / Patrone, Cesare

    Neurobiology of aging

    2020  Volume 89, Page(s) 12–23

    Abstract: The nigrostriatal dopaminergic system (NDS) controls motor activity, and its impairment during type 2 diabetes (T2D) progression could increase Parkinson's disease risk in diabetics. If so, whether glycemia regulation prevents this impairment needs to be ...

    Abstract The nigrostriatal dopaminergic system (NDS) controls motor activity, and its impairment during type 2 diabetes (T2D) progression could increase Parkinson's disease risk in diabetics. If so, whether glycemia regulation prevents this impairment needs to be addressed. We investigated whether T2D impairs the NDS and whether dipeptidyl peptidase-4 inhibition (DPP-4i; a clinical strategy against T2D but also neuroprotective in animal models) prevents this effect, in middle-aged mice. Neither T2D (induced by 12 months of high-fat diet) nor aging (14 months) changed striatal dopamine content assessed by high-performance liquid chromatography. However, T2D reduced basal and amphetamine-stimulated striatal extracellular dopamine, assessed by microdialysis. Both the DPP-4i linagliptin and the sulfonylurea glimepiride (an antidiabetic comparator unrelated to DPP-4i) counteracted these effects. The functional T2D-induced effects did not correlate with NDS neuronal/glial alterations. However, aging itself affected striatal neurons/glia, and the glia effects were counteracted mainly by DPP-4i. These findings show NDS functional pathophysiology in T2D and suggest the preventive use of two unrelated anti-T2D drugs. Moreover, DPP-4i counteracted striatal age-related glial alterations suggesting striatal rejuvenation properties.
    MeSH term(s) Aging/metabolism ; Animals ; Corpus Striatum/metabolism ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/metabolism ; Dipeptidyl-Peptidase IV Inhibitors/pharmacology ; Disease Progression ; Dopamine/metabolism ; Linagliptin/pharmacology ; Male ; Mice ; Mice, Inbred C57BL ; Models, Animal ; Parkinson Disease/etiology ; Parkinson Disease/prevention & control ; Risk ; Substantia Nigra/metabolism ; Sulfonylurea Compounds/pharmacology
    Chemical Substances Dipeptidyl-Peptidase IV Inhibitors ; Sulfonylurea Compounds ; Linagliptin (3X29ZEJ4R2) ; glimepiride (6KY687524K) ; Dopamine (VTD58H1Z2X)
    Language English
    Publishing date 2020-02-04
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 604505-4
    ISSN 1558-1497 ; 0197-4580
    ISSN (online) 1558-1497
    ISSN 0197-4580
    DOI 10.1016/j.neurobiolaging.2020.01.004
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Riluzole-Rasagiline Hybrids: Toward the Development of Multi-Target-Directed Ligands for Amyotrophic Lateral Sclerosis.

    Albertini, Claudia / Salerno, Alessandra / Atzeni, Silvia / Uliassi, Elisa / Massenzio, Francesca / Maruca, Annalisa / Rocca, Roberta / Mecava, Marko / Silva, Filomena S G / Mena, Débora / Valente, Pedro / Duarte, Ana I / Chavarria, Daniel / Bissaro, Maicol / Moro, Stefano / Federico, Stephanie / Spalluto, Giampiero / Soukup, Ondřej / Borges, Fernanda /
    Alcaro, Stefano / Monti, Barbara / Oliveira, Paulo J / Menéndez, Josè C / Bolognesi, Maria Laura

    ACS chemical neuroscience

    2022  Volume 13, Issue 15, Page(s) 2252–2260

    Abstract: Polypharmacology is a new trend in amyotrophic lateral sclerosis (ALS) therapy and an effective way of addressing a multifactorial etiology involving excitotoxicity, mitochondrial dysfunction, oxidative stress, and microglial activation. Inspired by a ... ...

    Abstract Polypharmacology is a new trend in amyotrophic lateral sclerosis (ALS) therapy and an effective way of addressing a multifactorial etiology involving excitotoxicity, mitochondrial dysfunction, oxidative stress, and microglial activation. Inspired by a reported clinical trial, we converted a riluzole (
    MeSH term(s) Amyotrophic Lateral Sclerosis/drug therapy ; Humans ; Indans ; Ligands ; Neuroprotective Agents/pharmacology ; Neuroprotective Agents/therapeutic use ; Riluzole/pharmacology ; Riluzole/therapeutic use
    Chemical Substances Indans ; Ligands ; Neuroprotective Agents ; rasagiline (003N66TS6T) ; Riluzole (7LJ087RS6F)
    Language English
    Publishing date 2022-07-22
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 1948-7193
    ISSN (online) 1948-7193
    DOI 10.1021/acschemneuro.2c00261
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top